[ CAS No. 51984-46-4 ] {[proInfo.proName]}

Name: 51984-46-4|(3-Methoxypyridin-2-yl)methanol|97%
Brand: Ambeed
SKU: A133790
Price: 31.0 USD
Availability: InStock
Rating: 96 (22 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 51984-46-4 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 51984-46-4 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 51984-46-4 ]

SDS Specification

Alternatived Products of [ 51984-46-4 ]

Product Details of [ 51984-46-4 ]

CAS No. :	51984-46-4	MDL No. :	MFCD08234494
Formula :	C₇H₉NO₂	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	RDXXAIGOEPIQPK-UHFFFAOYSA-N
M.W :	139.15	Pubchem ID :	5324774
Synonyms :

Calculated chemistry of [ 51984-46-4 ]

Physicochemical Properties

Num. heavy atoms :	10
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.29
Num. rotatable bonds :	2
Num. H-bond acceptors :	3.0
Num. H-bond donors :	1.0
Molar Refractivity :	36.86
TPSA :	42.35 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-7.17 cm/s

Lipophilicity

Log Po/w (iLOGP) :	1.61
Log Po/w (XLOGP3) :	-0.03
Log Po/w (WLOGP) :	0.43
Log Po/w (MLOGP) :	-0.39
Log Po/w (SILICOS-IT) :	1.17
Consensus Log Po/w :	0.56

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-1.0
Solubility :	14.0 mg/ml ; 0.101 mol/l
Class :	Very soluble
Log S (Ali) :	-0.41
Solubility :	54.2 mg/ml ; 0.39 mol/l
Class :	Very soluble
Log S (SILICOS-IT) :	-1.95
Solubility :	1.55 mg/ml ; 0.0111 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.57

Safety of [ 51984-46-4 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P280-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 51984-46-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 51984-46-4 ]
Downstream synthetic route of [ 51984-46-4 ]

[ 51984-46-4 ] Synthesis Path-Upstream 1~10

1
[ 51984-46-4 ]
[ 1849-53-2 ]

Reference： [1] Tetrahedron, 2005, vol. 61, # 3, p. 643 - 655
[2] Archiv der Pharmazie, 1992, vol. 325, # 1, p. 29 - 33

2
[ 31224-43-8 ]
[ 124-41-4 ]
[ 51984-46-4 ]

Yield	Reaction Conditions	Operation in experiment
45%	Stage #1: at 80℃; for 4 h; Stage #2: With sodium tetrahydroborate In methanol at 0℃; for 0.333333 h;	To a flask charged with 3-fluoropicolinaldehyde (400 mg, 3.20 mmol) was added sodium methoxide (15 mL, 7.50 mmol) (0.5M in MeOH ). The mixture was stirred at 80 ⁰C for 4h. The reaction mixture was then cooled to 0⁰C with an ice bath and NaBH₄ (90 mg, 2.38 mmol) was added to the mixture was stirred at 0⁰C for 20 min before ice was added to the mixture. After concentration in vacuo, the residue was purified with ISCO MPLC (40- 100percent EtOAc/hexane) to yield the title compound as a white solid (200 mg, 45.0 percent). ¹H NMR (DMSO-de) δ 8.11 (dd, 1 H), 7.41 (dd, 1 H), 7.31 (dd, 1 H), 4.83 (t, 1 H), 4.54 (d, 2 H), 3.82 (s, 3 H). MS (M+H⁺) = 140.

Reference： [1] Patent: WO2009/27746, 2009, A1, . Location in patent: Page/Page column 115

3
[ 14173-30-9 ]
[ 74-88-4 ]
[ 51984-46-4 ]

Yield	Reaction Conditions	Operation in experiment
7%	With potassium hydroxide In water; dimethyl sulfoxide	a 3-Methoxy(2-hydroxymethyl)pyridine To a mixture of ground potassium hydroxide (10.2 g, 0.186 mol) in dimethylsulphoxide (15 ml) under nitrogen was added 3-hydroxy(2-hydroxymethyl)pyridine hydrochloride (5.0 g, 0.031 mol) in dimethylsulphoxide (15 ml) over 0.25 h. The reaction was stirred at room temperature for 1 h before the addition of methyl iodide (1.92 ml, 0.0309 mol) and then stirred at room temperature overnight. Water (100 ml) was added and the solution acidified to pH 1 with 2N hydrochloric acid, washed with dichloromethane (3) and then basified with solid potassium carbonate until pH 12 was attained. The aqueous was extracted with dichloromethane (3), dried (MgSO₄), evaporated in vacuo and the residue purified by chromatography on silica gel, eluding with dichloromethane/methanol/ammonia (90:5:0.5), to give the title-compound (300 mg, 7percent). ¹H NMR (360 MHz, CDCl₃) δ 3.85 (3H, s, CH₃), 4.74 (2H, s, CH₂), 7.12 (1H, d, J=8.3 Hz, Ar-H), 7.21 (1H, m, Ar-H), 8.15 (1H, d, J=4.8 Hz, Ar-H).

Reference： [1] Journal of Medicinal Chemistry, 2005, vol. 48, # 5, p. 1367 - 1383
[2] Tetrahedron, 2005, vol. 61, # 3, p. 643 - 655
[3] Patent: US6200975, 2001, B1,

4
[ 24059-83-4 ]
[ 51984-46-4 ]

Reference： [1] ChemMedChem, 2016, vol. 11, # 23, p. 2607 - 2620
[2] Patent: WO2018/52903, 2018, A1, . Location in patent: Page/Page column 71
[3] Patent: US4083983, 1978, A,

5
[ 191799-01-6 ]
[ 51984-46-4 ]

Reference： [1] Journal of the Chemical Society. Perkin Transactions 2, 1997, # 3, p. 495 - 501

6
[ 35392-65-5 ]
[ 51984-46-4 ]

Reference： [1] Journal of Medicinal Chemistry, 1992, vol. 35, # 3, p. 438 - 450
[2] Journal of Medicinal Chemistry, 2018, vol. 61, # 19, p. 8811 - 8824

7
[ 191799-01-6 ]
[ 26395-26-6 ]
[ 51984-46-4 ]

Reference： [1] Journal of the Chemical Society. Perkin Transactions 2, 1997, # 3, p. 495 - 501

8
[ 874-24-8 ]
[ 51984-46-4 ]

Reference： [1] ChemMedChem, 2016, vol. 11, # 23, p. 2607 - 2620
[2] Patent: WO2018/52903, 2018, A1,

9
[ 62733-99-7 ]
[ 51984-46-4 ]

Reference： [1] ChemMedChem, 2016, vol. 11, # 23, p. 2607 - 2620
[2] Patent: WO2018/52903, 2018, A1,

10
[ 26395-26-6 ]
[ 51984-46-4 ]

Reference： [1] Journal of Medicinal Chemistry, 2018, vol. 61, # 19, p. 8811 - 8824

[ 51984-46-4 ] Synthesis Path-Downstream 1~48

1
[ 51984-46-4 ]
[ 1849-53-2 ]

Reference： [1]Tetrahedron,2005,vol. 61,p. 643 - 655
[2]Archiv der Pharmazie,1992,vol. 325,p. 29 - 33

2
[ 51984-46-4 ]
[ 215253-76-2 ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 438 - 450

3
(3-methoxypyridin-2-yl)methyl acetate [ No CAS ]
[ 51984-46-4 ]

Reference： [1]Journal of Medicinal Chemistry,2018,vol. 61,p. 8811 - 8824
[2]Journal of Medicinal Chemistry,1992,vol. 35,p. 438 - 450

4
(3-Methoxy-pyridin-2-yl)-piperidin-1-yl-methanone [ No CAS ]
[ 1849-53-2 ]
[ 51984-46-4 ]

Reference： [1]Journal of the Chemical Society. Perkin Transactions 2 (2001),1997,p. 495 - 501
[2]Journal of the Chemical Society. Perkin Transactions 2 (2001),1997,p. 495 - 501

5
(2,6-Dimethyl-piperidin-1-yl)-(3-methoxy-pyridin-2-yl)-methanone [ No CAS ]
[ 1849-53-2 ]
[ 51984-46-4 ]

Reference： [1]Journal of the Chemical Society. Perkin Transactions 2 (2001),1997,p. 495 - 501
[2]Journal of the Chemical Society. Perkin Transactions 2 (2001),1997,p. 495 - 501

6
[ 191799-01-6 ]
[ 26395-26-6 ]
[ 51984-46-4 ]

Reference： [1]Journal of the Chemical Society. Perkin Transactions 2 (2001),1997,p. 495 - 501

7
[ 191799-01-6 ]
[ 51984-46-4 ]
N-cyclohexyl-N-tert-butyl-2-aminomethyl-3-methoxypyridine [ No CAS ]

Reference： [1]Journal of the Chemical Society. Perkin Transactions 2 (2001),1997,p. 495 - 501

Yield	Reaction Conditions	Operation in experiment
		A) Preparation of 2-Hydroxymethyl-3-methoxy pyridine Potassium hydroxide (41.66 g,0.744 mol) was ground under nitrogen and stirred in DMSO (130 ml, anhydrous) for 20 min. 3-Hydroxy-2-hydroxymethyl pyridine hydrochloride [Aldrich] (47 g, 0.248 mol) was added and stirred for 30 rain in an ice bath. Methyl iodide (35.2 g, 0.248 mol, 15.43 ml) in DMSO (20 ml) was added dropwise to the solution and then allowed to stir overnight at room temperature. 5N HCl was added to pH 1 and the solution was extracted with dichloromethane (5500 ml). The aqueous was then basified with 5N NaOH to pH 14 and extracted with dichloromethane (3500 ml). The organics (base wash) were dried over sodium sulfate, and concentrated leaving tan colored crystals. The solid was recrystallized (50percent ethyl acetate/hexanes) providing 10.8 g (32percent) of the titled product as light tan crystals: mp 72° C.; IR (KBr, cm-1) 3080, 1575, 1459, 1424, 1278, 1218, 1066, 809; 1 H NMR (300 MHZ, DMSO-d6) delta8.5 (d,J=4.5 Hz,1H), 7.3 (d,J=8.3 Hz,1H), 7.25 (dd,J=8.2,4.6 Hz,1H), 4.77 (t,J=5.74 Hz,1H), 4.48 (d,J=5.6 Hz,2H), 3.77 (s,3H); MS (FD) m/e 139 (M+);
		c) (3-Methoxypyridin-2-yl)methanol Dimethylsulphoxide (15 ml) was added to ground potassium hydroxide (10.2 g, 0.186 mol) and stirred for 0.25 h at room temperature under nitrogen. 3-Hydroxy-(2 hydroxymethyl)pyridine hydrochloride (5.0 g, 0.031 mol) in dimethylsulphoxide (20 ml) was added via syringe. After stirring for 1 h, methyl iodide (1.92 ml, 0.031 mol) was added and the reaction stirred at room temperature overnight. Water (100 ml) was added and the mixture acidified to pH1 with 5N hydrochloric acid. The aqueous layer was washed with dichloromethane (3), basified to pH14 with sodium hydroxide and extracted with dichloromethane (4). The combined organic extracts were dried (MgSO4), the solvent removed in vacuo and the residue purified by chromatography eluding with dichloromethane/methanol/ammonia (90:5:0.5), to give the title-compound, 1H NMR (360 MHz, CDCl3) delta 3.86 (3H, d, J=1.8 Hz, CH3), 4.29 (1H, t, J=4.5 Hz, OH), 4.74 (2H, d, J=4.1 Hz, CH2), 7.12-7.22 (2H, m, 2 of Ar-H) and 8.15 (1H, d, J=4.7 Hz, Ar-H).

10
[ 51984-46-4 ]
[ 202931-56-4 ]
C₂₄H₂₃N₅O₂ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 1367 - 1383

11
[ 14173-30-9 ]
[ 74-88-4 ]
[ 51984-46-4 ]

Yield	Reaction Conditions	Operation in experiment
7%	With potassium hydroxide; In water; dimethyl sulfoxide;	a 3-Methoxy(2-hydroxymethyl)pyridine To a mixture of ground potassium hydroxide (10.2 g, 0.186 mol) in dimethylsulphoxide (15 ml) under nitrogen was added 3-hydroxy(2-hydroxymethyl)pyridine hydrochloride (5.0 g, 0.031 mol) in dimethylsulphoxide (15 ml) over 0.25 h. The reaction was stirred at room temperature for 1 h before the addition of methyl iodide (1.92 ml, 0.0309 mol) and then stirred at room temperature overnight. Water (100 ml) was added and the solution acidified to pH 1 with 2N hydrochloric acid, washed with dichloromethane (3) and then basified with solid potassium carbonate until pH 12 was attained. The aqueous was extracted with dichloromethane (3), dried (MgSO4), evaporated in vacuo and the residue purified by chromatography on silica gel, eluding with dichloromethane/methanol/ammonia (90:5:0.5), to give the title-compound (300 mg, 7percent). 1H NMR (360 MHz, CDCl3) delta 3.85 (3H, s, CH3), 4.74 (2H, s, CH2), 7.12 (1H, d, J=8.3 Hz, Ar-H), 7.21 (1H, m, Ar-H), 8.15 (1H, d, J=4.8 Hz, Ar-H).

Reference： [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 1367 - 1383
[2]Tetrahedron,2005,vol. 61,p. 643 - 655
[3]Patent: US6200975,2001,B1

12
[ 51984-46-4 ]
[ 139745-98-5 ]

Reference： [1]Tetrahedron,2005,vol. 61,p. 643 - 655
[2]Archiv der Pharmazie,1992,vol. 325,p. 29 - 33

13
[ 51984-46-4 ]
(Z)-isopropyl 3-(3-methoxypyridin-2-yl)acrylate [ No CAS ]

Reference： [1]Tetrahedron,2005,vol. 61,p. 643 - 655

14
[ 110-89-4 ]
2-<2,6-dihydroxy-3,5-dimethyl-phenoxy>-3,5-dinitro-benzophenone [ No CAS ]
[ 51984-46-4 ]

Reference： [1]Journal of the Chemical Society. Perkin Transactions 2 (2001),1997,p. 495 - 501

15
[ 51984-46-4 ]
(RS)-4-(3-methoxy-2-pyridinyl)pyrrolidin-2-one [ No CAS ]

Reference： [1]Archiv der Pharmazie,1992,vol. 325,p. 29 - 33

16
[ 51984-46-4 ]
[ 139745-99-6 ]

Reference： [1]Archiv der Pharmazie,1992,vol. 325,p. 29 - 33

17
[ 35392-65-5 ]
[ 51984-46-4 ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 438 - 450
[2]Journal of Medicinal Chemistry,2018,vol. 61,p. 8811 - 8824

18
[ 51984-46-4 ]
[ 122307-52-2 ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 438 - 450

19
[ 51984-46-4 ]
[ 122307-53-3 ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 438 - 450

20
[ 51984-46-4 ]
[ 111371-79-0 ]

Reference： [1]Journal of Medicinal Chemistry,1992,vol. 35,p. 438 - 450

21
[ 51984-46-4 ]
[ 149489-09-8 ]

Yield	Reaction Conditions	Operation in experiment
	With thionyl chloride; sodium carbonate; In methanol; water;	B) Preparation of 2-[(3-methoxy)pyridyl]acetonitrile Thionylchloride (100 ml) was added dropwise to <strong>[51984-46-4]2-Hydroxymethyl-3-methoxy pyridine</strong> (13.9 g, 0.1 mol) while stirring in an ice bath. After initial fuming subsided, the thionyl chloride was added more rapidly. The solution was then heated to reflux for 2 h. After cooling, the thionyl chloride was removed under reduced pressure leaving brown crystals. The solid was taken up in 190 ml methanol and potassium cyanide (19.4 g, 0.298 mol) dissolved in 80 ml of water was added to the methanolic solution. This solution was heated to reflux and allowed to reflux overnight. The solution was cooled down and 150 ml of saturated sodium carbonate was added and then poured into diethyl ether (500 ml). The solution was extracted 3 more times with 500 ml diethyl ether. The collected organics were washed with brine and saturated sodium bicarbonate. The organics were dried over sodium sulfate and concentrated giving 12.1 g (81.7%) of brown crystalline solid. This solid was used in the reduction without further purification: mp 71 C.; IR (KBr, cm-1) 3074, 2949, 2253, 1578, 1459, 1286, 1017, 821; 1 H NMR (300 MHZ, DMSO-d6) delta8.07 (m,1H), 7.43 (m,1H), 7.35 (m,1H), 4.0 (s,2H), 3.8 (s,3H); MS (FD) m/e 148 (M+);

Reference： [1]Patent: US5593993,1997,A

22
[ 24059-83-4 ]
[ 51984-46-4 ]

Yield	Reaction Conditions	Operation in experiment
	With methanol; sodium tetrahydroborate; at 0 - 20℃;	To the solution of methyl 3-methoxypieolinate (300 mg, 1 ,80 mmol) in 10 ml of fvleOH at 0eC was added NaBI-i? (304 mg, 8,04 mrnoi). The reaction was stirred overnight at room (0629) temperature. The completion of the reaction was monitored by HPLC. Upon completion, solvent was removed in vacuo, H2O was added to the crude residue and the reaction mixture was extracted with DC . The combined organic layers were washed with saturated aqueous NaHCCh, brine and dried over NaaSC . Filtration and removal .of the solvent provided 210 mg (84percent) of the title compound as a colorless oil, whicrwas used without further purification; 1H NMR (400 MHz, CDCI3) delta - 8.16 (dd, J ~ 1.3, 4.8 Hz, 1 H), 7,24 - 7.18 (m, 1 H), 7.17 - 7.1 1 (m, 1 H), 4,75 (d, J = 4.5 Hz, 2 H), 4.30 (t, J = 4.5 Hz, 1 H), 3.87 (s, 3 H)
	With sodium borohydrid; In methanol; ethanol; water;	Sodium borohydride (6.3 g) was added slowly over 75 minutes to a solution of <strong>[24059-83-4]3-methoxy-2-methoxycarbonylpyridine</strong> (9.2 g) in ethanol. Methanol (100 ml) was then added and after the initial vigorous reaction had subsided, further sodium borohydride (8.3 g) was added over a further 3 hours, and the mixture was left to stand overnight. The solvent was evaporated, the residue dissolved in water and extracted with chloroform and the chloroform solution dried. Evaporation, and crystallisation from ether gave 2-hydroxymethyl-3-methoxypyridine (4.4 g) m.p. 72.5°-73.5°.

Reference： [1]ChemMedChem,2016,vol. 11,p. 2607 - 2620
[2]Patent: WO2018/52903,2018,A1 .Location in patent: Page/Page column 71
[3]Patent: US4083983,1978,A

23
[ 51984-46-4 ]
2-chloromethyl-3-methoxypyridine hydrochloride [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With thionyl chloride; In chloroform;	(ii) 2-Hydroxymethyl-3-methoxypyridine (4.2 g) was dissolved in chloroform (60 ml) and the stirred solution was added thionyl chloride (6 ml). The mixture was stirred for 90 minutes and the solvent evaporated and the residue was recrystallized from ethanol/ether to give 2-chloromethyl-3-methoxypyridine hydrochloride (5.1 g), m.p. 171.5°-172.5°.

Reference： [1]Patent: US4083983,1978,A

24
[ 51984-46-4 ]
[ 935271-44-6 ]
(S)-tert-butyl 1-isopropyl-6-((3-methoxypyridin-2-yl)methoxy)-3,4-dihydroisoquinoline-2(1H)-carboxylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
20%	With triphenylphosphine; diethylazodicarboxylate; In tetrahydrofuran; at 0 - 20℃;	A mixture of (S)-tert-butyl 6-hydroxy-1-isopropyl-3,4-dihydroisoquinoline-2(1H)-carboxylate (25 mg, 0.086 mmol) and <strong>[51984-46-4](3-methoxypyridin-2-yl)methanol</strong> (17.9 mg, 0.129 mmol) in THF(1 mL) was cooled to 0° C. PPh3 (33.8 mg, 0.129 mmol) was added, followed by DEAD (20.3 muL, 0.129 mmol). The reaction mixture was warmed to room temperature and stirred overnight. It was concentrated and purified by column chromatography on ISCO (4 g) with 0-40percent hexanes in ethyl acetate over 25 minutes to yield Example 178 (7 mg, 20percent yield) as a colorless oil. HPLC retention time (Method C)=3.22 min. LC/MS (ESI) (M+H)+=413.4. 1H NMR (CDCl3, 400 MHz), 1:1 rotamers, delta ppm 0.90-0.99 (m, 6H), 1.40-1.47 (m, 9H), 1.90-2.01 (m, 1H), 2.77-2.89 (m, 2H), 3.34-3.51 (m, 1H), 3.68-3.76 (m, 0.5H), 3.88 (s, 3H), 4.02-4.12 (m, 0.5H), 4.63 (d, J=7.83 Hz, 0.5H), 4.75 (d, J=8.80 Hz, 0.5H), 6.80-6.89 (m, 2H), 7.02 (t, J=7.58 Hz, 1H), 7.20-7.28 (m, 2H), 8.24 (dd, J=4.52, 1.59 Hz, 1H).

Reference： [1]Patent: US2007/93523,2007,A1 .Location in patent: Page/Page column 64

25
[ 31224-43-8 ]
[ 124-41-4 ]
[ 51984-46-4 ]

Yield	Reaction Conditions	Operation in experiment
45.0%		To a flask charged with 3-fluoropicolinaldehyde (400 mg, 3.20 mmol) was added sodium methoxide (15 mL, 7.50 mmol) (0.5M in MeOH ). The mixture was stirred at 80 0C for 4h. The reaction mixture was then cooled to 00C with an ice bath and NaBH4 (90 mg, 2.38 mmol) was added to the mixture was stirred at 00C for 20 min before ice was added to the mixture. After concentration in vacuo, the residue was purified with ISCO MPLC (40- 100percent EtOAc/hexane) to yield the title compound as a white solid (200 mg, 45.0 percent). 1H NMR (DMSO-de) delta 8.11 (dd, 1 H), 7.41 (dd, 1 H), 7.31 (dd, 1 H), 4.83 (t, 1 H), 4.54 (d, 2 H), 3.82 (s, 3 H). MS (M+H+) = 140.

Reference： [1]Patent: WO2009/27746,2009,A1 .Location in patent: Page/Page column 115

26
4-bromo-2-hydroxy pyridine [ No CAS ]
[ 51984-46-4 ]
[ 1160791-23-0 ]

Yield	Reaction Conditions	Operation in experiment
	With triphenylphosphine; diethylazodicarboxylate; In dichloromethane; at 0 - 20℃;	(3-Methoxy-pyridin-2-yl)-methanol (227 mg, 1.63 mmol), 2-hydroxy-4-bromopyridine (282 mg, 1.63 mmol) and triphenyl phosphine (416 mg, 1.63 mmol) were stirred in dry dichloromethane (10 ml) at 0 0C under an atmosphere of nitrogen. Diethyl azodicarboxylate (242 mg, 1.63 mmol) was added at O0C then the reaction was allowed to attain room with stirring overnight. A saturated aqueous solution of sodium hydrogen carbonate was added (10 ml) and the layers were separated. The aqueous portion was extracted with dichloromethane (2x10 ml) and the organic portions were combined, dried (MgSO4) and concentrated under reduced pressure. The crude product was purified by flash silica chromatography eluting first with 0- 100percent ethyl acetate in petrol and then 10percent 7 N methanolic ammonia in dichloromethane to give the 4-bromo-1-(3-methoxy-pyridin-2-ylmethyl)-1/-/-pyridin-2- one in 57percent purity contaminated with 23percent 2-hydroxy-4-bromopyridine and 20percent triphenyl phosphine oxide by LC-MS (340 mg). The product was used directly in the next step. LC-MS m/z 297[M+H]+ Rt=2.05 min

Reference： [1]Patent: WO2009/74812,2009,A1 .Location in patent: Page/Page column 96

27
[ 51984-46-4 ]
[ 5122-82-7 ]
[ 1185752-82-2 ]

Yield	Reaction Conditions	Operation in experiment
	With caesium carbonate; In acetone; at 20℃; for 15h;	A mixture of <strong>[51984-46-4](3-methoxypyridin-2-yl)methanol</strong> (128 mg, 0.92 mmol), 1-adamantyl bromomethylketone (198 mg, 0.77 mmol) and caesium carbonate (500 mg, 1.53 mmol) in acetone (1OmL) was stirred at room temperature for 15h. The mixture was filtered, concentrated under vacuum and purified by flash chromatography (0-25percent-50percent Petrol <n="101"/>ether/EtOAc) to give the expected product (161 mg, 66.2percent yield) as clear yellow oil. Single TLC spot at R/0.6 (Pet. ether/EtOAc 5:5); 1H NMR (CDCl3, 270 MHz): .pound.1.63- 1.77 (m,6H), 1.83 (br s, 6H), 2.03 (br s, 3H), 3.88-3.91 (m, 3H), 4.42-4.46 (m, 2H), 4.57 (d, J= 3.0 Hz, 2H), 6.62 (dd, J= 8.4, 2.9 Hz, IH), 7.00-7.06 (m, IH), 7.57-7.60 (m, IH); ); LC/MS (ESI) t = 2.20 min m/z 316 (M++H); HPLC t = 3.05 min (91.83percent) in 10percent water-acetonitrile.

Reference： [1]ChemMedChem,2011,vol. 6,p. 1616 - 1629
[2]Patent: WO2009/106817,2009,A2 .Location in patent: Page/Page column 98-99

28
[ 898563-88-7 ]
[ 51984-46-4 ]
[ 1301167-98-5 ]

Reference： [1]Journal of Medicinal Chemistry,2011,vol. 54,p. 5820 - 5835

29
[ 51984-46-4 ]
[ 1301167-65-6 ]
[ 1301168-10-4 ]

Reference： [1]Journal of Medicinal Chemistry,2011,vol. 54,p. 5820 - 5835

30
[ 51984-46-4 ]
[ 1301167-65-6 ]
[ 1301168-11-5 ]

Reference： [1]Journal of Medicinal Chemistry,2011,vol. 54,p. 5820 - 5835

31
[ 51984-46-4 ]
[ 1301167-66-7 ]
[ 1301168-04-6 ]

Reference： [1]Journal of Medicinal Chemistry,2011,vol. 54,p. 5820 - 5835

32
[ 874-24-8 ]
[ 51984-46-4 ]

Reference： [1]ChemMedChem,2016,vol. 11,p. 2607 - 2620
[2]Patent: WO2018/52903,2018,A1

33
[ 62733-99-7 ]
[ 51984-46-4 ]

Reference： [1]ChemMedChem,2016,vol. 11,p. 2607 - 2620
[2]Patent: WO2018/52903,2018,A1

34
[ 51984-46-4 ]
2-(bromomethyl)-3-methoxypyridine [ No CAS ]

Reference： [1]ChemMedChem,2016,vol. 11,p. 2607 - 2620

35
[ 51984-46-4 ]
6-((3-methoxypyridin-2-yl)methoxy)-1-((3-(trifluoromethyl)phenyl)sulfonyl)indoline trifluoroacetate [ No CAS ]

Reference： [1]ChemMedChem,2016,vol. 11,p. 2607 - 2620

36
[ 51984-46-4 ]
N-methyl-N'-[2-(3-methoxy-pyridin-2-ylmethylthio)ethyl]guanidine [ No CAS ]

Reference： [1]Patent: US4083983,1978,A

37
[ 51984-46-4 ]
N-methyl-N'-[2-((3-methoxy-pyridin-2-yl)methylthio)ethyl]thiourea [ No CAS ]

Reference： [1]Patent: US4083983,1978,A

38
[ 51984-46-4 ]
1-methylthio-1-[2-((3-methoxy-pyridin-2-yl)methylthio)ethylamino]-2-nitroethylene [ No CAS ]

Reference： [1]Patent: US4083983,1978,A

39
[ 51984-46-4 ]
N-cyano-N'-[2-((3-methoxy-pyridin-2-yl)methylthio)ethyl]guanidine [ No CAS ]

Reference： [1]Patent: US4083983,1978,A

40
[ 51984-46-4 ]
[ 62734-01-4 ]

Reference： [1]Patent: US4083983,1978,A

41
[ 51984-46-4 ]
N-cyano-N'-methyl-N"-[2-((3-methoxy-2-pyridyl)methylthio)ethyl]guanidine [ No CAS ]

Reference： [1]Patent: US4083983,1978,A

42
[ 51984-46-4 ]
1-methylamino-1-[2-(3-methoxy-pyridin-2-ylmethylthio)ethylamino]-2-nitroethylene [ No CAS ]

Reference： [1]Patent: US4083983,1978,A

43
[ 51984-46-4 ]
[ 61832-51-7 ]

Reference： [1]Patent: US4083983,1978,A

44
[ 51984-46-4 ]
2-(bromomethyl)-3-methoxypyridine hydrogen bromide [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2018,vol. 61,p. 8811 - 8824

45
[ 51984-46-4 ]
di-tert-butyl 2,2'-((2-((2-(tert-butoxy)-2-oxoethyl)((3-methoxypyridin-2-yl)methyl)amino)cyclohexyl)azanediyl)diacetate [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2018,vol. 61,p. 8811 - 8824

46
[ 51984-46-4 ]
C₁₈H₂₅N₃O₇ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2018,vol. 61,p. 8811 - 8824

47
[ 51984-46-4 ]
C₁₉H₂₇N₃O₇ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2018,vol. 61,p. 8811 - 8824

48
[ 26395-26-6 ]
[ 51984-46-4 ]

Reference： [1]Journal of Medicinal Chemistry,2018,vol. 61,p. 8811 - 8824

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 51984-46-4 ]

Ethers

[ 1849-53-2 ]

3-Methoxypicolinaldehyde

Similarity: 0.84

[ 24059-89-0 ]

3-Methoxypicolinonitrile

Similarity: 0.84

[ 1588441-00-2 ]

(3-Methoxypyridin-2-yl)methanamine hydrochloride

Similarity: 0.82

[ 16478-52-7 ]

3-Methoxypicolinic acid

Similarity: 0.82

[ 16665-38-6 ]

(4-Methoxypyridin-2-yl)methanol

Similarity: 0.80

Alcohols

[ 1121-25-1 ]

2-Methylpyridin-3-ol

Similarity: 0.86

[ 16665-38-6 ]

(4-Methoxypyridin-2-yl)methanol

Similarity: 0.80

[ 1122-43-6 ]

2,6-Dimethyl-3-hydroxypyridine

Similarity: 0.76

[ 3308-02-9 ]

2-Phenylpyridin-3-ol

Similarity: 0.76

[ 62733-99-7 ]

Methyl 3-hydroxypicolinate

Similarity: 0.76

Related Parent Nucleus of
[ 51984-46-4 ]

Pyridines

[ 1121-25-1 ]

2-Methylpyridin-3-ol

Similarity: 0.86

[ 1849-53-2 ]

3-Methoxypicolinaldehyde

Similarity: 0.84

[ 24059-89-0 ]

3-Methoxypicolinonitrile

Similarity: 0.84

[ 1588441-00-2 ]

(3-Methoxypyridin-2-yl)methanamine hydrochloride

Similarity: 0.82

[ 16478-52-7 ]

3-Methoxypicolinic acid

Similarity: 0.82

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 51984-46-4 ] {[proInfo.proName]}

Quality Control of [ 51984-46-4 ]

Related Doc. of [ 51984-46-4 ]

Product Details of [ 51984-46-4 ]

Calculated chemistry of [ 51984-46-4 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 51984-46-4 ]

Application In Synthesis of [ 51984-46-4 ]

[ 51984-46-4 ] Synthesis Path-Upstream 1~10

[ 51984-46-4 ] Synthesis Path-Downstream 1~48

Related Functional Groups of [ 51984-46-4 ]

Ethers

Alcohols

Related Parent Nucleus of [ 51984-46-4 ]

Pyridines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 51984-46-4 ]

Related Parent Nucleus of
[ 51984-46-4 ]